İntravitreal Bevacizumab ile Tedavi Edilen Prematüre Retinopatili Bebeklerde Risk Faktörlerinin Değerlendirilmesi.

Objective: To analyze the relationship between the severity of retinopathy in premature infants and risk factors in the mother and infant. Methods: The medical records of the infants who were followed up at Dicle University Faculty of Medicine due to retinopathy of premature (ROP) between June 2017 and October 2020 were retrospectively evaluated. Birth age, birth weight, accompanying comorbid diseases during the follow-up period, and pregnancy problems of the mother were recorded. Those who were followed up without treatment (group 1) and those who received intravitreal bevacizumab treatment (group 2) were compared. Results: One hundred sixty seven premature infants were included in the study. Ninety nine of them (60%) had ROP that did not require treatment (group 1), 68 (40%) were administered intravitreal bevacizumab (group 2). While the gestational age and birth weight of group 2 were significantly lower than group 1 (p <0.001 and p <0.001), no difference was found in terms of gender distributions (p = 0.387). Respiratory Distress Syndrome (RDS) was significantly more common in premature infants who received intravitreal treatment (p = 0.010). Birth weight was found to be a significant independent risk factor in logistic regression analysis (p = 0.048; 95% CI, 0.993-1.00). The rates of twin to twin transfusion, Rh incompatibility, chorioamnionitis, and premature rupture of membranes were similar in the two groups (p> 0.05). Discussion: Low birth weight is a significant independent risk factor in infants with retinopathy of prematurity requiring treatment. Large-scale, multi-center studies are needed to better reveal the effect of risk factors. [ABSTRACT FROM AUTHOR]